ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance.
Massimiliano MelloneKlaudia PiotrowskaGiulia VenturiLija JamesAleksandra BzuraMaria A LopezSonya JamesChuan WangMatthew J EllisChristopher J HanleyJosephine F BuckinghamKerry L CoxGareth HughesViia Valge-ArcherEmma V KingStephen A BeersVincent JaquetGeorge D D JonesNatalia SavelyevaA Emre SayanJason L ParsonsStephen T DurantGareth J ThomasPublished in: Cancer research (2022)
ATM signaling supports the differentiation of myoCAFs to suppress T-cell infiltration and antitumor immunity, supporting the potential clinical use of ATM inhibitors in combination with checkpoint inhibition in myoCAF-rich, immune-cold tumors.